|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 11/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -0.08% | -1.43% | +15.87% | +67.24% | 47.71B | ||
| -3.21% | +1.37% | +51.19% | +124.26% | 40.3B | ||
| -0.40% | -1.23% | -10.08% | +17.30% | 12.09B | ||
| +1.11% | -1.34% | +13.27% | +72.07% | 11.68B | ||
| +0.19% | +0.58% | +30.98% | +151.21% | 9.19B | ||
| -0.39% | -0.92% | +20.49% | +39.85% | 7.57B | ||
| -1.35% | +0.74% | +47.38% | -12.13% | 7.24B | ||
| -0.64% | -0.02% | +19.65% | +205.39% | 6.84B | ||
| -5.36% | -6.36% | -38.04% | +19.49% | 5.42B | ||
| Average | -1.01% | -1.20% | +16.75% | +76.07% | 15.38B | |
| Weighted average by Cap. | -1.10% | -0.62% | +24.08% | +83.63% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















